MONROVIA, Calif. , May 28, 2014 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been

MONROVIA, Calif. , May 22, 2014 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma

Conference call today at 4:30 p.m. EDT

MONROVIA, Calif. , May 7, 2014 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter

MONROVIA, Calif. , April 29, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,

MONROVIA, Calif. , April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a

MONROVIA, Calif. , March 28, 2014 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific

MONROVIA, Calif. , March 24, 2014 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,

Conference call to be held today at 4:30 p.m. EDT

MONROVIA, Calif. , March 13, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and

MONROVIA, Calif. , Feb. 6, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D., Chief

MONROVIA, Calif. , Dec. 6, 2013 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their

Xencor Prices Initial Public Offering MONROVIA, Calif. , Dec. 3, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR ) today announced the pricing of its initial public offering of 12,730,000 shares of its common stock at a public offering price of $5.50 per share.

Xencor Files Registration Statement for Proposed Initial Public Offering MONROVIA, Calif., October 11, 2013— Xencor, Inc. today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its

MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 (XmAb5574) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and US-based Xencor, Inc. today announced completion of the phase 1/2a clinical trial evaluating MOR208 (formerly XmAb®5574) in patients with

MONROVIA, Calif., October 1, 2013—Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies

Xencor Licenses Fc Antibody Engineering IP to Merck MONROVIA, Calif., July 2, 2013 – Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the United States and Canada, access to one of Xencor's Fc

Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia MONROVIA, Calif., April 26, 2013 – Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic

Xencor Licenses Xtend ™ Therapeutic Protein Half-life Extension Technology to CSL MONROVIA, Calif., and MELBOURNE, Australia, April 16, 2013—Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend™

Xencor Initiates Phase 1b/2a Trial of XmAbR5871 for Autoimmune Disease MONROVIA, Calif., February 13, 2013—Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis.

MONROVIA, Calif., January 17, 2013—Xencor, Inc. today announced it has received a milestone payment from Janssen Research & Development, LLC (Janssen R&D) resulting from the exercised option for the use of Xencor's Xtend™ half-life extension technology in a therapeutic antibody.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical

Martinsried/Munich, Germany, and Monrovia, Calif., USA, May 22, 2012—MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

SEVENTH ANTIBODY DEVELOPED WITH XENCOR'S XmAb TECHNOLOGY MOVES INTO HUMAN TRIALS

Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement MONROVIA, Calif., April 4, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.

Antibodies engineered with Xencor's proprietary Xtend&#8482 technology for increasing antibody half-life

Xencor Initiates Phase 1 Study of XmAb ® 5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response Monrovia, Calif. – Oct. 21, 2011 – Xencor, Inc., a company using its

Monrovia, Calif. – March 9, 2011 – Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (FcyRIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell

Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Thousand Oaks, Calif. and Monrovia, Calif. – (Jan. 6, 2011) – Amgen (NASDAQ: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered

Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia Monrovia, Calif. – December 2, 2010 – Xencor, Inc. and MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208),

Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Monrovia, CA—October 12, 2010 – Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program Martinsried/Munich, Germany, and Monrovia, Calif. – June 28, 2010 – MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) and US-based biopharmaceutical company Xencor, Inc., announced today the

Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer Monrovia, Calif. – February 9, 2010 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief

Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Monrovia, Calif. – January 19, 2010 – A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies

Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Monrovia, CA—December 16, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone

Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board Monrovia, CA—December 7, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Bruce Carter, Ph.D.

Xencor Licenses Antibody Optimization Technology Monrovia, Calif. – November 30, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology

Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board Monrovia, CA—June 29, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, today announced the addition of Jeffrey Ravetch,

Drug well tolerated with early signs of efficacy in heavily pretreated Hodgkin lymphoma patient population

First clinical data from a candidate developed using Xencor's antibody engineering platform

Xencor Licenses Xtend ™ Antibody Half-life Prolongation Platform to Merck & Co., Inc. Monrovia, CA – March 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a licensing transaction with Merck & Co., Inc.

Monrovia, CA – March 2, 2009. Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies.

Xencor and CSL Limited Establish Antibody Optimization Collaboration Monrovia, CA – February 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd.

Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology Monrovia, Calif. – December 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented results Sunday at the 50th

Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference Monrovia, Calif. – December 2, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485

Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO Monrovia, Calif. – June 1, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it will present new data from pre-clinical studies evaluating XmAb®5574, an Fc engineered monoclonal

Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR Monrovia, Calif. – April 15, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented data from its anti-CD19 antibody program during the Annual Meeting of the American Association for Cancer Research

Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings Monrovia, Calif. – April 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical CD19 program for lymphoma and leukemias at the Annual Meeting of the

Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors Monrovia, CA — March 19, 2008 — Xencor, Inc., a company developing protein and antibody therapeutics, today announced that it appointed David R. King as Chairman of its Board of Directors. To Xencor, Mr.